Who is sponsoring NCT04455958?

NCT04455958 is sponsored by OHSU Knight Cancer Institute.

What drugs are being tested in NCT04455958?

Interventions in NCT04455958: Lopinavir/Ritonavir, Placebo Administration, Questionnaire Administration.

What condition does NCT04455958 study?

NCT04455958 studies Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed.

Is NCT04455958 still recruiting?

NCT04455958 is currently withdrawn. Last updated 26 April 2021.

Last reviewed 2021-04-26 · How we verify

NCT04455958

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year

Withdrawn Phase 2 Last updated 26 April 2021

What this trial tests

Phase 2 trial testing Lopinavir/Ritonavir in Hematopoietic and Lymphoid Cell Neoplasm. Withdrawn.

Timeline

1 May 2021

Primary endpoint
1 November 2021

1 November 2021

Quick facts

Lead sponsor	OHSU Knight Cancer Institute
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Start date	1 May 2021
Primary completion	1 November 2021
Estimated completion	1 November 2021

Drugs / interventions tested

Lopinavir/Ritonavir
Placebo Administration — full drug profile →
Questionnaire Administration

Conditions studied

Hematopoietic and Lymphoid Cell Neoplasm — all drugs for Hematopoietic and Lymphoid Cell Neoplasm →
Malignant Solid Neoplasm — all drugs for Malignant Solid Neoplasm →
Symptomatic COVID-19 Infection Laboratory-Confirmed — all drugs for Symptomatic COVID-19 Infection Laboratory-Confirmed →

Sponsor

OHSU Knight Cancer Institute

Who can join

18 and older, any sex, with Hematopoietic and Lymphoid Cell Neoplasm or Malignant Solid Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies how well lopinavir/ritonavir works in treating COVID-19 positive patients with cancer and a weakened immune system (immune-suppression) in the last year and have mild or moderate symptoms caused by COVID-19. Lopinavir/ritonavir may help to lessen or prevent COVID-19 symptoms from getting worse in cancer patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Altered metabolism in cancer: insights into energy pathways and therapeutic targets.
Tufail M, Jiang CH, Li N. · · 2024 · cited 265× · PMID 39294640 · DOI 10.1186/s12943-024-02119-3
Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2.
Chiotos K, Hayes M, Kimberlin DW, Jones SB, et al · · 2021 · cited 74× · PMID 32918548 · DOI 10.1093/jpids/piaa115
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895
Adjunctive Nutraceutical Therapies for COVID-19.
Subedi L, Tchen S, Gaire BP, Hu B, et al · · 2021 · cited 28× · PMID 33669456 · DOI 10.3390/ijms22041963
The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy.
Kouhpayeh S, Shariati L, Boshtam M, Rahimmanesh I, et al · · 2021 · cited 26× · PMID 34064039 · DOI 10.3390/ijms22115438
Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment.
Zou H, Yang Y, Dai H, Xiong Y, et al · · 2021 · cited 12× · PMID 34880750 · DOI 10.3389/fphar.2021.732403
Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19.
Malek RJ, Bill CA, Vines CM. · · 2021 · cited 9× · PMID 34624681 · DOI 10.1016/j.biopha.2021.112276
The prospects of employing probiotics in combating COVID-19.
Chakraborty M, Munshi SK. · · 2022 · cited 3× · PMID 35465282 · DOI 10.4103/tcmj.tcmj_104_21

Verify or expand the search:

Other trials of Lopinavir/Ritonavir

Trials testing the same drug.

NCT04521400 — the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in · Phase 2 · unknown
NCT04351724 — Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) · Phase 2, PHASE3 · unknown
NCT04425382 — Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar · completed
NCT01854762 — Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection · Phase 2, PHASE3 · terminated
NCT01148004 — The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volu · Phase 1 · completed

Other recruiting trials for Hematopoietic and Lymphoid Cell Neoplasm

Currently open trials in the same condition.

NCT05711667 — A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patien · Phase 3 · recruiting
NCT06184321 — Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion · EARLY_PHASE1 · recruiting
NCT06089408 — Weighted Blanket Use to Reduce Anxiety in Oncology Patients · NA · recruiting
NCT05663502 — Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers · recruiting
NCT05178472 — Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria) · NA · recruiting

Other OHSU Knight Cancer Institute trials

Trials by the same sponsor.

NCT05453851 — A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatme · Phase 1, PHASE2 · not yet recruiting
NCT07511504 — Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanc · Phase 2 · not yet recruiting
NCT07434128 — Mammogram Pretreatment With Ulipristal Acetate · Phase 2 · not yet recruiting
NCT07504835 — GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer · NA · not yet recruiting
NCT07498517 — Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04455958 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by OHSU Knight Cancer Institute
Last refreshed: 26 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04455958.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing